Foundayo Starting Dose
The recommended starting dose of Foundayo (orforglipron) is 0.8 mg orally once daily. 1
Dosing Administration
- Take once daily, with or without food
- Swallow tablets whole—do not break, crush, or chew
- Do not take more than one tablet per day 1
Dose Escalation Schedule
The FDA-approved dosing follows a structured escalation protocol to minimize gastrointestinal adverse reactions 1:
Mandatory escalation timeline:
- Week 0-4: Start at 0.8 mg once daily
- Week 4-8: Increase to 2.5 mg once daily (after at least 30 days on 0.8 mg)
- Week 8-12: Increase to 5.5 mg once daily (after at least 30 days on 2.5 mg)
- Week 12+: May increase to 9 mg, 14.5 mg, or 17.2 mg once daily based on treatment response and tolerability (minimum 30 days between each escalation)
Maximum dose: 17.2 mg once daily 1
Critical Dosing Considerations
If 7 or more consecutive doses are missed: You must reinitiate dose escalation at a lower dose to reduce gastrointestinal adverse reaction risk. Do not resume at the previous dose. 1
Drug interactions requiring dose modification:
- Strong CYP3A4 inhibitors: Maximum dose is 9 mg once daily (avoid if the inhibitor also inhibits OATP1B)
- Strong CYP3A4 inducers: Avoid concomitant use
- Moderate CYP3A4 inducers: Monitor effectiveness and escalate as needed 1
Clinical Context
This gradual escalation strategy is essential because gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) are the most common side effects and are predominantly dose-dependent, occurring mainly during dose escalation 2, 3. In clinical trials, treatment discontinuation due to adverse events ranged from 5.3-10.3% with orforglipron versus 2.7% with placebo, with gastrointestinal events being the primary driver 3.
The 0.8 mg starting dose represents a carefully calibrated entry point that balances tolerability with the need to achieve therapeutic doses. Clinical trial data demonstrate that higher doses (24-36 mg, equivalent to 14.5-17.2 mg tablet formulation) provide optimal weight loss efficacy, with the 36 mg dose achieving mean weight reductions of approximately 11% at 72 weeks 3, 4.